10/567,797

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 6	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 8	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS 10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS 11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS 12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS 13	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 14	DEC 18	CA/CAplus patent kind codes updated
NEWS 15	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS 17	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS 18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 19	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 22	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 23	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 24	JAN 29	PHAR reloaded with new search and display fields
NEWS 25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:07:08 ON 08 FEB 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:07:32 ON 08 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN.CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 FEB 2007 HIGHEST RN 919834-45-0
DICTIONARY FILE UPDATES: 7 FEB 2007 HIGHEST RN 919834-45-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10567797.str





chain nodes :
13 15 17 18
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
2-13 10-18 11-15 15-17
ring bonds :
1-2 1-6 2-3 3-4 3-7 4-5 4-9 5-6 5-10 6-12 7-8 8-9 10-11 11-12
exact/norm bonds :
1-2 1-6 2-3 2-13 3-4 3-7 4-5 4-9 5-6 5-10 6-12 7-8 8-9 10-11 10-18
11-12 11-15 15-17
isolated ring systems :
containing 1 :

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 15:CLASS 17:Atom 18:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 13:08:03 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 5 TO 234
PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 13:08:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 65 TO ITERATE

100.0% PROCESSED 65 ITERATIONS 10 ANSWERS
SEARCH TIME: 00.00.01

L3 10 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY 172.10 TOTAL SESSION 172.31

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 13:08:12 ON 08 FEB 2007

FILE COVERS 1907 - 8 Feb 2007 VOL 146 ISS 7
FILE LAST UPDATED: 7 Feb 2007 (20070207/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 full
L4 1 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:158670 CAPLUS
DOCUMENT NUMBER: 142:261549
TITLE: Preparation of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidine derivatives as glutamate racemase inhibitors
INVENTOR(S): Basarab, Gregory S.; Eyermann, Charles J.; Gowravaram, Madhusudhan R.; Green, Oluyinka; Kiely, Andrew; MacPherson, Lawrence J.; Morningstar, Marshall L.; Thanh, Nguyen
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005016929	A1	20050224	WO 2004-GB3464		20040812
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1664052	A1	20060607	EP 2004-743692		20040812
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
US 2006252781	A1	20061109	US 2006-567797		20060209
PRIORITY APPLN. INFO.:			US 2003-495615P	P	20030815
			WO 2004-GB3464	W	20040812

OTHER SOURCE(S): CASREACT 142:261549; MARPAT 142:261549
GI



I



II

AB Title compds. represented by the formula I [wherein A = N or (un)substituted C; R = H, halo, (un)substituted alkyl, sulfide, etc.; R2 = H, (un)substituted (cyclo)alkyl, alkenyl, aryl, etc.; R3 = (un)substituted hetero(bi)cyclic ring; and pharmaceutically acceptable salts thereof] were prepared as glutamate racemase inhibitors. For example, II was given in a multi-step synthesis starting from the reaction of 6-chlorouracil with cyclopropylmethyl bromide. I showed inhibition of glutamate racemase with IC50 values of less than 400 uM. Thus, I and their pharmaceutical compns. are useful as glutamate racemase inhibitors for the treatment or prophylaxis of H. pylori infection.

IT 845729-13-7P, 5-[8-[(6-Chloroquinolin-4-yl)methyl]-6-(cyclopropylmethyl)-5-oxo-6,8-dihydro-5H-pyrazolo[4,3-e]-[1,2,4]triazolo[4,3-c]pyrimidin-9-yl]-1-methyl-1H-pyrrole-3-carbonitrile 845729-14-8P, 5-[8-[(6-Chloroquinolin-4-yl)methyl]-6-(cyclopropylmethyl)-3-methyl-5-oxo-6,8-dihydro-5H-pyrazolo[4,3-e]-[1,2,4]triazolo[4,3-c]pyrimidin-9-yl]-1-methyl-1H-pyrrole-3-carbonitrile 845729-15-9P, 5-[8-[(6-Chloroquinolin-4-yl)methyl]-6-(cyclopropylmethyl)-3-(dimethylamino)-5-oxo-6,8-dihydro-5H-pyrazolo[4,3-e]-[1,2,4]triazolo[4,3-c]pyrimidin-9-yl]-1-methyl-1H-pyrrole-3-carbonitrile 845729-16-0P, 5-[3-Amino-8-[(6-chloroquinolin-4-yl)methyl]-6-(cyclopropylmethyl)-5-oxo-6,8-dihydro-5H-pyrazolo[4,3-e]-[1,2,4]triazolo[4,3-c]pyrimidin-9-yl]-1-methyl-1H-pyrrole-3-carbonitrile 845729-17-1P, 5-[8-[(6-Chloroquinolin-4-yl)methyl]-6-(cyclopropylmethyl)-5-oxo-6,8-dihydro-5H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-9-yl]-1-methyl-1H-pyrrole-3-carbonitrile 845729-18-2P, 8-[(6-Chloroquinolin-4-yl)methyl]-6-(cyclopropylmethyl)-9-(1-methyl-1H-imidazol-5-yl)-6,8-dihydro-5H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-5-one 845729-19-3P, 8-[[5-Chloro-1-(methylsulfonyl)-1H-indol-3-yl]methyl]-6-(cyclopropylmethyl)-9-(1-methyl-1H-imidazol-5-yl)-6,8-dihydro-5H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-5-one 845729-20-6P, 8-[(6-Chloroquinolin-4-yl)methyl]-6-(cyclopropylmethyl)-9-[1-methyl-4-(methylsulfonyl)-1H-pyrrol-2-yl]-6,8-dihydro-5H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-5-one 845729-21-7P, 5-[8-[[5-Chloro-1-(methylsulfonyl)-1H-indol-3-yl]methyl]-6-(cyclopropylmethyl)-5-oxo-6,8-dihydro-5H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-9-yl]-1-methyl-1H-pyrrole-3-carbonitrile 845729-22-8P, 5-[8-[(6-Chloroquinolin-4-yl)methyl]-6-(cyclopropylmethyl)-3-methyl-5-oxo-6,8-dihydro-5H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-9-yl]-1-methyl-1H-pyrrole-3-carbonitrile
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidine derivs. as glutamate racemase inhibitors)

RN 845729-13-7 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[8-[(6-chloro-4-quinolinyl)methyl]-6-(cyclopropylmethyl)-6,8-dihydro-5-oxo-5H-pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-9-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 845729-14-8 CAPLUS
CN 1H-Pyrrole-3-carbonitrile, 5-[8-[(6-chloro-4-quinolinyl)methyl]-6-(cyclopropylmethyl)-6,8-dihydro-3-methyl-5-oxo-5H-pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-9-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 845729-15-9 CAPLUS
CN 1H-Pyrrole-3-carbonitrile, 5-[8-[(6-chloro-4-quinolinyl)methyl]-6-(cyclopropylmethyl)-3-(dimethylamino)-6,8-dihydro-5-oxo-5H-pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-9-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 845729-16-0 CAPLUS
CN 1H-Pyrrole-3-carbonitrile, 5-[3-amino-8-[(6-chloro-4-quinolinyl)methyl]-6-(cyclopropylmethyl)-6,8-dihydro-5-oxo-5H-pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-9-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 845729-17-1 CAPLUS
CN 1H-Pyrrole-3-carbonitrile, 5-[8-[(6-chloro-4-quinolinyl)methyl]-6-(cyclopropylmethyl)-6,8-dihydro-5-oxo-5H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-9-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 845729-18-2 CAPLUS
CN 5H-Imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-5-one, 8-[(6-chloro-4-quinolinyl)methyl]-6-(cyclopropylmethyl)-6,8-dihydro-9-(1-methyl-1H-imidazol-5-yl)- (9CI) (CA INDEX NAME)



RN 845729-19-3 CAPLUS
CN 5H-Imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-5-one, 8-[[5-chloro-1-(methylsulfonyl)-1H-indol-3-yl]methyl]-6-(cyclopropylmethyl)-6,8-dihydro-9-

(1-methyl-1H-imidazol-5-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 845729-20-6 CAPLUS
CN 5H-Imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-5-one, 8-[(6-chloro-4-quinolinyl)methyl]-6-(cyclopropylmethyl)-6,8-dihydro-9-[1-methyl-4-(methylsulfonyl)-1H-pyrrol-2-yl]- (9CI) (CA INDEX NAME)



RN 845729-21-7 CAPLUS
CN 1H-Pyrrole-3-carbonitrile, 5-[8-[[5-chloro-1-(methylsulfonyl)-1H-indol-3-yl]methyl]-6-(cyclopropylmethyl)-6,8-dihydro-5-oxo-5H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-9-yl]-1-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 845729-22-8 CAPLUS
CN 1H-Pyrrole-3-carbonitrile, 5-[8-[(6-chloro-4-quinolinyl)methyl]-6-(cyclopropylmethyl)-6,8-dihydro-3-methyl-5-oxo-5H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-9-yl]-1-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 13:07:08 ON 08 FEB 2007)

FILE 'REGISTRY' ENTERED AT 13:07:32 ON 08 FEB 2007
L1 STRUCTURE UPLOADED
L2 1 S L1
L3 10 S L1 FULL

FILE 'CAPLUS' ENTERED AT 13:08:12 ON 08 FEB 2007
L4 1 S L3 FULL

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.74	178.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.78	-0.78

STN INTERNATIONAL LOGOFF AT 13:08:49 ON 08 FEB 2007

10/567,797

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 6	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 8	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS 10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS 11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS 12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS 13	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 14	DEC 18	CA/CAplus patent kind codes updated
NEWS 15	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS 17	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS 18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 19	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 22	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 23	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 24	JAN 29	PHAR reloaded with new search and display fields
NEWS 25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:21:25 ON 08 FEB 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:21:38 ON 08 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 FEB 2007 HIGHEST RN 919834-45-0
DICTIONARY FILE UPDATES: 7 FEB 2007 HIGHEST RN 919834-45-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10567797b.str





ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
ring bonds :
1-2 1-6 2-3 3-4 3-7 4-5 4-9 5-6 5-10 6-12 7-8 8-9 10-11 11-12
exact/norm bonds :
1-2 1-6 2-3 3-4 3-7 4-5 4-9 5-6 5-10 6-12 7-8 8-9 10-11 11-12

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS
L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 13:22:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 93 TO ITERATE

100.0% PROCESSED 93 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1282 TO 2438
PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 13:22:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1711 TO ITERATE

100.0% PROCESSED 1711 ITERATIONS 25 ANSWERS
SEARCH TIME: 00.00.01

L3 25 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.55 172.76

FILE 'CAPLUS' ENTERED AT 13:22:44 ON 08 FEB 2007

FILE COVERS 1907 - 8 Feb 2007 VOL 146 ISS 7
FILE LAST UPDATED: 7 Feb 2007 (20070207/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 full
L4 2 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:158670 CAPLUS
DOCUMENT NUMBER: 142:261549
TITLE: Preparation of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidine derivatives as glutamate racemase inhibitors
INVENTOR(S): Basarab, Gregory S.; Eyermann, Charles J.; Gowravaram, Madhusudhan R.; Green, Oluyinka; Kiely, Andrew; MacPherson, Lawrence J.; Morningstar, Marshall L.; Thanh, Nguyen
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005016929	A1	20050224	WO 2004-GB3464		20040812
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1664052	A1	20060607	EP 2004-743692		20040812
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
US 2006252781	A1	20061109	US 2006-567797		20060209
PRIORITY APPLN. INFO.:			US 2003-495615P	P	20030815
			WO 2004-GB3464	W	20040812

OTHER SOURCE(S): CASREACT 142:261549; MARPAT 142:261549
GI



I



II

AB Title compds. represented by the formula I [wherein A = N or (un)substituted C; R = H, halo, (un)substituted alkyl, sulfide, etc.; R2 = H, (un)substituted (cyclo)alkyl, alkenyl, aryl, etc.; R3 = (un)substituted hetero(bi)cyclic ring; and pharmaceutically acceptable salts thereof] were prepared as glutamate racemase inhibitors. For example, II was given in a multi-step synthesis starting from the reaction of 6-chlorouracil with cyclopropylmethyl bromide. I showed inhibition of glutamate racemase with IC50 values of less than 400 uM. Thus, I and their pharmaceutical compns. are useful as glutamate racemase inhibitors for the treatment or prophylaxis of H. pylori infection.

IT 845729-13-7P, 5-[8-[(6-Chloroquinolin-4-yl)methyl]-6-(cyclopropylmethyl)-5-oxo-6,8-dihydro-5H-pyrazolo[4,3-e]-[1,2,4]triazolo[4,3-c]pyrimidin-9-yl]-1-methyl-1H-pyrrole-3-carbonitrile 845729-14-8P, 5-[8-[(6-Chloroquinolin-4-yl)methyl]-6-(cyclopropylmethyl)-3-methyl-5-oxo-6,8-dihydro-5H-pyrazolo[4,3-e]-[1,2,4]triazolo[4,3-c]pyrimidin-9-yl]-1-methyl-1H-pyrrole-3-carbonitrile 845729-15-9P, 5-[8-[(6-Chloroquinolin-4-yl)methyl]-6-(cyclopropylmethyl)-3-(dimethylamino)-5-oxo-6,8-dihydro-5H-pyrazolo[4,3-e]-[1,2,4]triazolo[4,3-c]pyrimidin-9-yl]-1-methyl-1H-pyrrole-3-carbonitrile 845729-16-0P, 5-[3-Amino-8-[(6-chloroquinolin-4-yl)methyl]-6-(cyclopropylmethyl)-5-oxo-6,8-dihydro-5H-pyrazolo[4,3-e]-[1,2,4]triazolo[4,3-c]pyrimidin-9-yl]-1-methyl-1H-pyrrole-3-carbonitrile 845729-17-1P, 5-[8-[(6-Chloroquinolin-4-yl)methyl]-6-(cyclopropylmethyl)-5-oxo-6,8-dihydro-5H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-9-yl]-1-methyl-1H-pyrrole-3-carbonitrile 845729-18-2P, 8-[(6-Chloroquinolin-4-yl)methyl]-6-(cyclopropylmethyl)-9-(1-methyl-1H-imidazol-5-yl)-6,8-dihydro-5H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-5-one 845729-19-3P, 8-[[5-Chloro-1-(methylsulfonyl)-1H-indol-3-yl]methyl]-6-(cyclopropylmethyl)-9-(1-methyl-1H-imidazol-5-yl)-6,8-dihydro-5H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-5-one 845729-20-6P, 8-[(6-Chloroquinolin-4-yl)methyl]-6-(cyclopropylmethyl)-9-[1-methyl-4-(methylsulfonyl)-1H-pyrrol-2-yl]-6,8-dihydro-5H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-5-one 845729-21-7P, 5-[8-[[5-Chloro-1-(methylsulfonyl)-1H-indol-3-yl]methyl]-6-(cyclopropylmethyl)-5-oxo-6,8-dihydro-5H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-9-yl]-1-methyl-1H-pyrrole-3-carbonitrile 845729-22-8P, 5-[8-[(6-Chloroquinolin-4-yl)methyl]-6-(cyclopropylmethyl)-3-methyl-5-oxo-6,8-dihydro-5H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-9-yl]-1-methyl-1H-pyrrole-3-carbonitrile
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidine derivs. as glutamate racemase inhibitors)

RN 845729-13-7 CAPLUS

CN 1H-Pyrrole-3-carbonitrile, 5-[8-[(6-chloro-4-quinolinyl)methyl]-6-(cyclopropylmethyl)-6,8-dihydro-5-oxo-5H-pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-9-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 845729-14-8 CAPLUS
CN 1H-Pyrrole-3-carbonitrile, 5-[8-[(6-chloro-4-quinolinyl)methyl]-6-(cyclopropylmethyl)-6,8-dihydro-3-methyl-5-oxo-5H-pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-9-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 845729-15-9 CAPLUS
CN 1H-Pyrrole-3-carbonitrile, 5-[8-[(6-chloro-4-quinolinyl)methyl]-6-(cyclopropylmethyl)-3-(dimethylamino)-6,8-dihydro-5-oxo-5H-pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-9-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 845729-16-0 CAPLUS
CN 1H-Pyrrole-3-carbonitrile, 5-[3-amino-8-[(6-chloro-4-quinolinyl)methyl]-6-(cyclopropylmethyl)-6,8-dihydro-5-oxo-5H-pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-9-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 845729-17-1 CAPLUS
CN 1H-Pyrrole-3-carbonitrile, 5-[8-[(6-chloro-4-quinolinyl)methyl]-6-(cyclopropylmethyl)-6,8-dihydro-5-oxo-5H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-9-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 845729-18-2 CAPLUS
CN 5H-Imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-5-one, 8-[(6-chloro-4-quinolinyl)methyl]-6-(cyclopropylmethyl)-6,8-dihydro-9-(1-methyl-1H-imidazol-5-yl)- (9CI) (CA INDEX NAME)



RN 845729-19-3 CAPLUS
CN 5H-Imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-5-one, 8-[[5-chloro-1-(methylsulfonyl)-1H-indol-3-yl]methyl]-6-(cyclopropylmethyl)-6,8-dihydro-9-

(1-methyl-1H-imidazol-5-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 845729-20-6 CAPLUS
CN 5H-Imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-5-one, 8-[(6-chloro-4-quinolinyl)methyl]-6-(cyclopropylmethyl)-6,8-dihydro-9-[1-methyl-4-(methylsulfonyl)-1H-pyrrol-2-yl]- (9CI) (CA INDEX NAME)



RN 845729-21-7 CAPLUS
CN 1H-Pyrrole-3-carbonitrile, 5-[8-[[5-chloro-1-(methylsulfonyl)-1H-indol-3-yl]methyl]-6-(cyclopropylmethyl)-6,8-dihydro-5-oxo-5H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-9-yl]-1-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 845729-22-8 CAPLUS
CN 1H-Pyrrole-3-carbonitrile, 5-[8-[(6-chloro-4-quinolinyl)methyl]-6-(cyclopropylmethyl)-6,8-dihydro-3-methyl-5-oxo-5H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-9-yl]-1-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:302773 CAPLUS
DOCUMENT NUMBER: 135:92613
TITLE: A facile synthesis of pyrimido[2",3":5',1']pyrazolo[3',4':4,5]pyrimido[1,6-a]benzimidazoles and [1,2,4]triazino[3",4":5',1']pyrazolo[3',4':4,5]-pyrimido[6,1-a]benzimidazoles
AUTHOR(S): Abdelhamid, Abdou O.; Zohdi, Hussein F.; Ziada, Mahmoud M.

CORPORATE SOURCE: Department of Chemistry, Faculty of Science, Cairo University, Giza, Egypt
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (2001), 40B(4), 284-289
CODEN: IJSBDB; ISSN: 0376-4699
PUBLISHER: National Institute of Science Communication, CSIR
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:92613

AB Thieno[2',3':4,5]pyrimido[1,6-a]benzimidazoles were prepared by the reaction of 3-mercaptopyrimido[1,6-a]benzimidazole with halo ketones and halo esters, resp. 3-Aminopyrazolo[3',4':5,6]pyrimido[1,6-a]benzimidazole reacted with acetylacetone, Et acetoacetate, Et benzoylacetate, Et α-chloroacetoacetate and β-aryl-α-cyanoacrylonitriles to give pyrimido[2",3":5',1']pyrazolo[3',4':4,5]pyrimido[1,6-a]benzimidazoles. A diazonium salt coupled with each of malononitrile, benzoylacetonitrile, acetylacetone, di-Et malonate and β-keto esters to give [1,2,4]triazino[3",4":5',1']pyrazolo[3',4':4,5]pyrimido[6,1-a]benzimidazoles.

IT 349123-76-8P 349123-77-9P 349123-78-0P
349123-80-4P 349123-81-5P 349123-82-6P
349123-83-7P 349123-84-8P 349123-85-9P
349123-86-0P 349123-87-1P 349123-88-2P
349123-89-3P 349123-90-6P 349123-91-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of triazinopyrazolopyrimidobenzimidazoles and pyrimidopyrazolopyrimidobenzimidazoles)

RN 349123-76-8 CAPLUS
CN Pyrimido[1'',2'':1',5']pyrazolo[3',4':4,5]pyrimido[1,6-a]benzimidazole-2,8(1H,7H)-dione, 4,7-diphenyl- (9CI) (CA INDEX NAME)



RN 349123-77-9 CAPLUS
CN Pyrimido[1'',2'':1',5']pyrazolo[3',4':4,5]pyrimido[1,6-a]benzimidazol-8(7H)-one, 2,4-dimethyl-7-phenyl- (9CI) (CA INDEX NAME)



RN 349123-78-0 CAPLUS
CN Pyrimido[1'',2'':1',5']pyrazolo[3',4':4,5]pyrimido[1,6-a]benzimidazole-2,8(1H,7H)-dione, 4-methyl-7-phenyl- (9CI) (CA INDEX NAME)



RN 349123-80-4 CAPLUS
CN Pyrimido[1'',2'':1',5']pyrazolo[3',4':4,5]pyrimido[1,6-a]benzimidazole-2,8(1H,7H)-dione, 3-chloro-4-methyl-7-phenyl- (9CI) (CA INDEX NAME)



RN 349123-81-5 CAPLUS
CN Pyrimido[1'',2'':1',5']pyrazolo[3',4':4,5]pyrimido[1,6-a]benzimidazole-3-carbonitrile, 4-amino-1,2,7,8-tetrahydro-8-oxo-2,7-diphenyl- (9CI) (CA INDEX NAME)



RN 349123-82-6 CAPLUS
CN Pyrimido[1'',2'':1',5']pyrazolo[3',4':4,5]pyrimido[1,6-a]benzimidazole-3-carbonitrile, 4-amino-1,2,7,8-tetrahydro-2-(4-methoxyphenyl)-8-oxo-7-phenyl- (9CI) (CA INDEX NAME)



RN 349123-83-7 CAPLUS
CN Pyrimido[1'',2'':1',5']pyrazolo[3',4':4,5]pyrimido[1,6-a]benzimidazole-3-carbonitrile, 4-amino-2-(4-chlorophenyl)-1,2,7,8-tetrahydro-8-oxo-7-phenyl- (9CI) (CA INDEX NAME)



RN 349123-84-8 CAPLUS
CN Pyrimido[1'',2'':1',5']pyrazolo[3',4':4,5]pyrimido[1,6-a]benzimidazole-3-carbonitrile, 4-amino-1,2,7,8-tetrahydro-8-oxo-7-phenyl-2-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 349123-85-9 CAPLUS
CN Pyrimido[1'',2'':1',5']pyrazolo[3',4':4,5]pyrimido[1,6-a]benzimidazole-3-carbonitrile, 4-amino-2-(2-furanyl)-1,2,7,8-tetrahydro-8-oxo-7-phenyl- (9CI) (CA INDEX NAME)



RN 349123-86-0 CAPLUS
CN [1,2,4]Triazino[4'',3'':1',5']pyrazolo[3',4':4,5]pyrimido[1,6-a]benzimidazole-3-carbonitrile, 4-amino-7,8-dihydro-8-oxo-7-phenyl- (9CI) (CA INDEX NAME)



RN 349123-87-1 CAPLUS
CN [1,2,4]Triazino[4'',3'':1',5']pyrazolo[3',4':4,5]pyrimido[1,6-a]benzimidazole-3-carbonitrile, 7,8-dihydro-8-oxo-4,7-diphenyl- (9CI) (CA INDEX NAME)



RN 349123-88-2 CAPLUS
CN [1,2,4]Triazino[4'',3'':1',5']pyrazolo[3',4':4,5]pyrimido[1,6-a]benzimidazol-8(7H)-one, 3-acetyl-4-methyl-7-phenyl- (9CI) (CA INDEX NAME)



RN 349123-89-3 CAPLUS
CN [1,2,4]Triazino[4'',3'':1',5']pyrazolo[3',4':4,5]pyrimido[1,6-a]benzimidazole-3-carboxylic acid, 1,4,7,8-tetrahydro-4,8-dioxo-7-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 349123-90-6 CAPLUS
CN [1,2,4]Triazino[4'',3'':1',5']pyrazolo[3',4':4,5]pyrimido[1,6-a]benzimidazole-3-carboxylic acid, 7,8-dihydro-4-methyl-8-oxo-7-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 349123-91-7 CAPLUS
CN [1,2,4]Triazino[4'',3'':1',5']pyrazolo[3',4':4,5]pyrimido[1,6-a]benzimidazole-3-carboxylic acid, 7,8-dihydro-8-oxo-4,7-diphenyl-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.01	183.77

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.56	-1.56

FILE 'STNGUIDE' ENTERED AT 13:23:15 ON 08 FEB 2007

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb 2, 2007 (20070202/UP).

=> d his

(FILE 'HOME' ENTERED AT 13:21:25 ON 08 FEB 2007)

FILE 'REGISTRY' ENTERED AT 13:21:38 ON 08 FEB 2007
L1 STRUCTURE UPLOADED
L2 1 S L1

```
L3            25 S L1 FULL

      FILE 'CAPLUS' ENTERED AT 13:22:44 ON 08 FEB 2007
L4             2 S L3 FULL

      FILE 'STNGUIDE' ENTERED AT 13:23:15 ON 08 FEB 2007

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.06     183.83

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -1.56

STN INTERNATIONAL LOGOFF AT 13:23:49 ON 08 FEB 2007
```